DMT Analog

Psychedelics biotech Cybin Inc. (NYSE:CYBN) has received clearance from the Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for CYB004, its novel deuterated DMT molecule for Generalized Anxiety Disorder (GAD) treatment. This will enable the company to initiate a...

Next-generation R&D psychedelics company Psilera Inc. shared its two proprietary DMT analogs PSIL-001 and PSIL-002’s preclinical positive results for mental health disorder treatments.  Psilera uses machine-learning methods to map complex datasets and identify early-stage lead...